Table 2 Comparison of adjuvant therapy trials with bisphosphonates in different patient collectives.

Trial	n	Patient description	CHT	Bisphosphonate therapy	Median FU	HR for DFS	HR for OS	Reference
AZURE all patients	3 360	stage II/III	95 %	zoledronate 4 mg, 6 × q3-4w, 8 × q3m, 5 × q6m	60 m	0.98 (p = 0.79)	1.01 (p = 0.93)	Coleman, 2011 42
AZURE postmenopausal patients	1 101	stage II/III postmenopausal	95 %	zoledronate 4 mg, 6 × q3-4w, 8 × q3m, 5 × q6m	60 m	0.71 (p = 0.0017)	0.71 (p = 0.017)	Coleman, 2011 42
ABCSG-12	1 803	premenopausal	< 5 %	zoledronate 4 mg, 6 × q6m	84 m	0.72 (p = 0.014)	0.63 (p = 0.0049)	Gnant, 2009 41
ZOFAST	1 065	postmenopausal	0 %	zoledronate 4 mg, 6 × q6m	60 m	0.66 (p = 0.0375)	n. s.	de Boer, 2011 28
NSABP-B34	3 323	all stages	65 %	clodronate 1 600 mg/d over 5 years	101 m	0.91 (p = 0.27)	0.84 (p = 0.13)	Paterson, 2011 32
Powles	1 069	all stages	?	clodronate 1 600 mg/d over 2 years	88 m	0.77 (p = 0.127)	0.77 (p = 0.047)	Powles, 2002 44
Diel	302	DTC in KM	40 %	clodronate 1 600 mg/d over 2 years	103 m	0.98 (p = 0.222)	0.83 (p = 0.049)	Diel, 2008 43
Sarto	296	nodal positive	90 %	clodronate 1 600 mg/d over 2 years	98 m	n. s.	n. s.